DrugPatentWatch Database Preview
Tirofiban hydrochloride - Generic Drug Details
What are the generic sources for tirofiban hydrochloride and what is the scope of tirofiban hydrochloride freedom to operate?
Tirofiban hydrochloride
is the generic ingredient in one branded drug marketed by Medicure and is included in two NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Tirofiban hydrochloride has twelve patent family members in six countries.
There are four drug master file entries for tirofiban hydrochloride. One supplier is listed for this compound.
Summary for tirofiban hydrochloride
| International Patents: | 12 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 2 |
| Drug Master File Entries: | 4 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 144 |
| Clinical Trials: | 40 |
| Patent Applications: | 5,379 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | tirofiban hydrochloride at DailyMed |
Pharmacology for tirofiban hydrochloride
| Drug Class | Platelet Aggregation Inhibitor |
| Physiological Effect | Decreased Platelet Aggregation |
Synonyms for tirofiban hydrochloride
| (2S)-2-(butane-1-sulfonamido)-3-{4-[4-(piperidin-4-yl)butoxy]phenyl}propanoic acid |
| (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid |
| (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid hydrate hydrochloride |
| (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid hydrochloride |
| (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid hydrochloride monohydrate |
| (2S)-2-(BUTYLSULFONYLAMINO)-3-[4-[4-(4-PIPERIDYL)BUTOXY]PHENYL]PROPANOIC ACID |
| (2S)-2-(butylsulfonylamino)-3-[4-[4-(4-piperidyl)butoxy]phenyl]propanoic acid hydrate hydrochloride |
| (2S)-2-(butylsulfonylamino)-3-[4-[4-(4-piperidyl)butoxy]phenyl]propanoic acid hydrochloride |
| (2S)-2-(Butylsulfonylamino)-3-[4-[4-(4-piperidyl)butoxy]phenyl]propanoic acid hydrochloride hydrate |
| (2S)-2-(Butylsulfonylamino)-3-{4-[4-(4-piperidyl)butoxy}phenyl propanoic acid |
| (2S)-2-(Butylsulfonylamino)-3-{4-[4-(4-piperidyl)butoxy}phenyl propanoic acid, N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine |
| (S)-2-(BUTANE-1-SULFONYLAMINO)-3-[4-(4-PIPERIDIN-4-YL-BUTOXY)-PHENYL]-PROPIONIC ACID HCL HYDRATE |
| (S)-2-(butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoic acid |
| (S)-2-(Butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoic acid hydrochloride |
| (S)-2-(Butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoic acid hydrochloride hydrate |
| 140430-EP2277565A2 |
| 140430-EP2277566A2 |
| 140430-EP2277567A1 |
| 140430-EP2277568A2 |
| 140430-EP2277569A2 |
| 140430-EP2277570A2 |
| 140430-EP2292280A1 |
| 142373-60-2 |
| 142373-60-2 (hydrochloride) |
| 144494-65-5 |
| 144494-65-5 (Parent) |
| 150915-40-5 |
| 151065-53-1 |
| 373T602 |
| 494T655 |
| 6H925F8O5J |
| 915T405 |
| AB0005248 |
| AB1009554 |
| AC1L1U7L |
| AC1L1U7O |
| AC1L21WW |
| AC1Q3ETP |
| AC1Q3ETQ |
| AC1Q6VFB |
| ACT04424 |
| AGG |
| Aggrastat |
| Aggrastat (TN) |
| aggrestat |
| Agrastat |
| Agrastat (TN) |
| AK326111 |
| AK326170 |
| AKOS015894972 |
| AKOS025311245 |
| AKOS027327567 |
| AN-15411 |
| AN-31474 |
| AN-7594 |
| API0005653 |
| API0014445 |
| AS-11027 |
| AX8154227 |
| AX8154228 |
| BDBM50004058 |
| BG0585 |
| BIDD:GT0363 |
| C07965 |
| C22H36N2O5S |
| C22H36N2O5S.HCl |
| C22H39ClN2O6S |
| CAS-150915-40-5 |
| CCG-222411 |
| CHEBI:9605 |
| CHEBI:9606 |
| CHEMBL1704 |
| CHEMBL3189072 |
| CHEMBL916 |
| COKMIXFXJJXBQG-NRFANRHFSA-N |
| CS-0948 |
| CS-2829 |
| CT0258 |
| CTK4C6811 |
| D01029 |
| D08607 |
| D0BN9X |
| DB00775 |
| DR002726 |
| DSSTox_CID_28561 |
| DSSTox_GSID_48635 |
| DSSTox_RID_82833 |
| DTXSID20162730 |
| DTXSID5048635 |
| EBD44261 |
| FT-0675251 |
| FT-0773940 |
| GGX234SI5H |
| GTPL6586 |
| HSDB 7323 |
| HY-17369 |
| HY-17369B |
| IKE1P4X57J |
| J-524973 |
| KB-269052 |
| KB-61743 |
| KS-00000H6G |
| KS-00000XQQ |
| L 700462 |
| L-700,462 |
| L-700462 |
| L-Tyrosine, N-(butylsulfonyl)-O-(4-(4-piperidinyl)butyl)- |
| L-Tyrosine, N-(butylsulfonyl)-O-(4-(4-piperidinyl)butyl)-, monohydrochloride |
| L-Tyrosine, N-(butylsulfonyl)-O-(4-(4-piperidinyl)butyl)-, monohydrochloride, monohydrate |
| L700462;MK383 |
| LS-173142 |
| LS-173214 |
| MFCD00868210 |
| MFCD05237246 |
| MFCD07368623 |
| MK 383 |
| MK-383 |
| MK-383 Hydrochloride |
| MolPort-006-167-632 |
| MolPort-006-823-927 |
| MolPort-027-806-963 |
| N-(Butylsulfonyl)-4-(4-(4-piperidyl)butoxy)-L-phenylalanine monohydrochloride monohydrate |
| N-(Butylsulfonyl)-O-(4-(4-piperidinyl)butyl)-L-tyrosine monohydrochloride |
| N-(Butylsulfonyl)-O-(4-(4-piperidinyl)butyl)-L-tyrosine monohydrochloride monohydrate |
| N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine |
| N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine |
| N-(butylsulfonyl)-O-(4-piperidin-4-ylbutyl)-L-tyrosine hydrochloride monohydrate |
| N-(BUTYLSULFONYL)-O-[4-(4-PIPERIDINYL)BUTYL]-L-TYROSINE |
| N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine hydrochloride |
| N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine Monohydrochloride Monohydrate |
| N-(Butylsulfonyl)-O-[4-(4-piperidynyl)butyl]-L-tyrosine Hydrochloride Hydrate |
| n-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine |
| n-(butylsulfonyl)-o-[4-(piperidin-4-yl)butyl]-l-tyrosine hydrochloride(1:1) |
| N-(n-butanesulfonyl)-O-(4-(4-piperidinyl)-butyl)-(s)-tyrosine |
| NCGC00182085-01 |
| NCGC00263584-01 |
| Q-101314 |
| RL01804 |
| RT-016037 |
| s3085 |
| s8594 |
| SC-27175 |
| SC-96683 |
| SCHEMBL3685 |
| SCHEMBL41325 |
| SCHEMBL41327 |
| tirofiban |
| Tirofiban (hydrochloride monohydrate) |
| Tirofiban (INN) |
| Tirofiban [BAN:INN] |
| Tirofiban [INN:BAN] |
| Tirofiban HCl |
| Tirofiban HCl hydrate |
| Tirofiban Hydrochloride (anhydrous) |
| tirofiban hydrochloride (monohydrate) |
| Tirofiban hydrochloride (USAN) |
| Tirofiban hydrochloride [USAN] |
| Tirofiban hydrochloride anhydrous |
| Tirofiban hydrochloride hydrate |
| Tirofiban hydrochloride monohydrate |
| Tirofiban hydrochloride monohydrate, >=98% (HPLC) |
| Tirofiban, >=98.5% (HPLC) |
| Tirofiban, Hydrochloride Hydrate |
| Tirofiban[BAN:INN] |
| TIROFIBANHYDROCHLORIDEMONOHYDRATE |
| tirofibanum |
| Tox21_112980 |
| Tox21_112980_1 |
| UNII-6H925F8O5J |
| UNII-GGX234SI5H |
| UNII-IKE1P4X57J |
| W-5345 |
| Y0428 |
| ZINC3806104 |
US Patents and Regulatory Information for tirofiban hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicure | AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020913-001 | May 14, 1998 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Medicure | AGGRASTAT | tirofiban hydrochloride | SOLUTION;INJECTION | 020912-002 | Aug 31, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Medicure | AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020913-001 | May 14, 1998 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Medicure | AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020913-003 | Apr 20, 2000 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for tirofiban hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Medicure | AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020912-001 | May 14, 1998 | ➤ Sign Up | ➤ Sign Up |
| Medicure | AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020912-001 | May 14, 1998 | ➤ Sign Up | ➤ Sign Up |
| Medicure | AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020913-002 | May 17, 2002 | ➤ Sign Up | ➤ Sign Up |
| Medicure | AGGRASTAT | tirofiban hydrochloride | INJECTABLE;INJECTION | 020912-001 | May 14, 1998 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
International Patents for tirofiban hydrochloride
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 9938827 | ➤ Sign Up |
| Australia | 2003234596 | ➤ Sign Up |
| Japan | 2002501936 | ➤ Sign Up |
| United Kingdom | 9809793 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for tirofiban hydrochloride
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 90040 | Netherlands | ➤ Sign Up | PRODUCT NAME: TIROFIBAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF EEN HYDRAAT, IN HET BIJZONDER TIROFIBANHY- DROCHLORIDE MONOHYDRAAT; NATL REGISTRATION NO/DATE: RVG 23380-1 19990707; FIRST REGISTRATION: DE 42618.00.00-01 19980630 |
| 00C/002 | Belgium | ➤ Sign Up | PRODUCT NAME: TIROFIBANUM HYDROCHLORIDUM (EQ. TIROFIBAN); NAT. REGISTRATION NO/DATE: 922 IS 191 F 12 19990906; FIRST REGISTRATION: CH 54761 19980528 |
| C/GB99/042 | United Kingdom | ➤ Sign Up | PRODUCT NAME: TIROFIBAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE HYDROCHLORIDE; REGISTERED: LI 54761 19980528; CH 54761 19980528; DE 42618.00.00 19980630; DE 42618.00.01 19980630; DE 42620.00.00 19980630; DE 42620.00.01 19980630; UK PL 00025/0375 19990715; UK PL 00025/0376 19990715 |
| /1999 | Austria | ➤ Sign Up | PRODUCT NAME: TIROFIBAN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: 1-23140 UND 1-23141 19990714; FIRST REGISTRATION: LI IKS-NR 54761 19980528 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: